Marillion Pharmaceuticals Initiates Clinical Development of Novel Anticancer Drug
Posted on: Wednesday, 24 October 2007, 09:00 CDT
Marillion Pharmaceuticals, Inc., a privately-held development-stage pharmaceutical company focused on novel therapeutics for the treatment of cancer, inflammatory and autoimmune diseases, announced today that its investigational new drug application (IND) has been cleared by the FDA. Marillion is now able to proceed with its planned Phase 1 human clinical trial for the company's lead product candidate, MN-201, an orally administered vitamin D5 analog for the treatment of cancer.
The Phase I trial will be an open-label, dose-escalation study to evaluate the safety and pharmacology of MN-201 in patients with advanced tumors in various cancers. The protocol for the clinical trial is currently before institutional review boards (IRBs) at the sites selected for the trial and clinical supplies are being prepared.
"MN-201 is the first synthetic vitamin D5 receptor ligand (VDRL) to be advanced into clinical trials for a variety of cancers including breast, prostate and colon cancers," said Zahed Subhan, Ph.D, chief executive officer of Marillion Pharmaceuticals. "Based on a novel mechanism of action, MN-201 could have utility as both a monotherapy in the treatment of various malignancies and for use in combination with other chemotherapeutic agents where synergistic benefits may be possible," added Dr. Subhan.
In preclinical studies, MN-201 demonstrated broad anti-tumor activity in cancer cells. In animal models, oral administration of MN-201 also resulted in anti-tumor activity including tumor regression in xenograft models of major solid tumor types. In contrast to treatment with other vitamin D(3) analogs and the naturally occurring vitamin D hormone, calcitriol, favorable anticancer effects with MN-201 were observed in the absence of significantly raised calcium levels.
About Marillion Pharmaceuticals
Marillion Pharmaceuticals is an emerging pharmaceuticals company dedicated to the development and commercialization of novel therapeutics for the treatment of cancers, inflammatory and autoimmune diseases. Marillion's product pipeline addresses unmet medical needs with a target market that is expected to grow significantly, reaching more than $1 billion annually by 2010 in North America alone. Marillion is a spin-out company from the University of Pennsylvania and was founded in February 2005 following seed funding received from BioAdvance. Series A funding was received from APIDC/Venture East. Visit www.marillionpharma.com for more information.
Source: Business Wire
Related Articles
- Systems Biology Recommends A New Clinical Approach To Cancer
- Cornerstone Pharmaceuticals Announces Approval to Conduct Phase I/II Clinical Trial of CPI-613 in Cancer Patients By US FDA
- OncoGenex Reports Updated Survival Data on OGX-011 in a Second-Line Chemotherapy Trial for Patients With Prostate Cancer
- VioQuest Pharmaceuticals Enters Into Clinical Trial Agreement for Novel Akt Inhibitor VQD-002 With the National Cancer Institute
- Vitamin D Linked to Reduced Cancer Risk; Cancer Society Advises Supplements
- Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of SNS-595 in Ovarian Cancer
- NeoRx Initiates Clinical Trial of Picoplatin in Colorectal Cancer and Announces Name Change to Poniard Pharmaceuticals and Relocation of Corporate Headquarters
- ARIMIDEX(R) (Anastrozole) Gains Full FDA Approval for Adjuvant Treatment of Hormone Receptor-Positive Early Breast Cancer in Postmenopausal Women
- First Melanoma Patients Complete Treatment in Provectus Phase 1 Clinical Trial of PV-10
- NeoRx Announces Treatment of First Patient With Picoplatin in Phase 2 Clinical Trial in Small Cell Lung Cancer
 |
 |
User Comments (0)
RSS Feeds